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Abstract. We evaluated the association between mild cognitive impairment (MCI) subtypes and quality of life (QoL) in 219 newly
diagnosed Parkinson’s disease (PD) patients without dementia. Participants completed neuropsychological tests of attention,
executive function, visuospatial function, memory, and language, and reported QoL using the Parkinson’s Disease Questionnaire.
Impairments were most common in executive function, memory and attention. MCI subtypes were classified according to
Movement Disorder Society Task Force criteria. More severe cognitive impairment was associated with poorer quality of life
(p = 0.01), but subtype of impairment was not (p > 0.10), suggesting that the nature of cognitive impairment is less significant
than its severity.
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INTRODUCTION
For the individual living with Parkinson’s disease
(PD), the development of dementia (PDD) has a sig-
nificant impact upon quality of life (QoL) [1]. Mild
cognitive impairment in PD (PD-MCI) may be a pre-
cursor to PDD, and thus may also impact on QoL
[2]. Furthermore, QoL may be affected by particular
subtypes of MCI [1], where impairments in multi-
ple domains may have greater cognitive burden and
thus may cause greater difficulties in activities of daily
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living (ADL) and poorer QoL [3, 4]. Additionally, spe-
cific domains, e.g. deficits in attention and executive
function which are common in PD, may be more detri-
mental to ADL and QoL [4–6].
To the authors’ knowledge, there are currently no
studies investigating whether QoL in people with PD-
MCI differs between subtypes. Such information could
help guide clinicians as to what pharmacological and
non-pharmacological interventions might be particu-
larly effective [7]; e.g. cholinesterase inhibitors for
attention could improve QoL [5, 8].
We evaluated the impact of PD-MCI subtypes upon
QoL in a large cohort of patients with newly diagnosed
PD. We hypothesised that PD-MCI would negatively
affect QoL and that the effect across the different MCI
subtypes would not be equal, with executive dysfunc-
tion and attention having a greater impact.
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PARTICIPANTS AND METHODS
Newly diagnosed idiopathic PD patients, as per
Queen’s Square Brain Bank criteria [9], were recruited
from community and outpatient clinics. Participants
and age-sex matched healthy controls completed a
schedule of neuropsychological assessments covering
five cognitive domains: attention, executive function,
visuospatial function, language and memory [10].
Attention was assessed using Power of Attention and
Digit vigilance from the Cognitive Drug Research Bat-
tery [11]. Executive function was assessed using the
One touch Tower of London from the Cambridge Neu-
ropsychological Test Automated Battery (CANTAB)
[12], phonemic fluency (number of words generated in
60 seconds beginning with the letter F) and semantic
fluency (number of names of animals generated in 90
seconds) [13, 14]. Memory was assessed using Spatial
and Pattern Recognition Memory, and Paired Asso-
ciate Learning subsets from the CANTAB. Visuospa-
tial dysfunction was measured using a modified scoring
for copying interlocking pentagons [15]. Language
dysfunction was measured using the naming and lan-
guage scores from the Montreal Cognitive Assessment
(MoCA) [16]. Premorbid intelligence was measured
using the National Adult Reading Test (NART) [17].
As our study design predated the Movement Disor-
der Society (MDS) Task Force PD-MCI criteria, we
used a modified Level II criteria, which is described in
full elsewhere [10], at cut offs of 1.0, 1.5 or 2.0 standard
deviations (SD) below normative values (controls)
to classify PD-MCI. For non-normally distributed
neuropsychological scores, an approximation to the
normal distribution was used to calculate cut-offs.
Single-domain PD-MCI was defined as impairment
in two tests in the same domain; multi-domain clas-
sification required at least one impaired test in more
than one domain [18]. Participants were then classified
according to impairments in specific domains.
The Parkinson’s Disease Questionnaire (PDQ-39)
single index score was used to assess QoL [19], where
a score of 0 indicates best QoL and a maximum score of
100 indicates worst QoL. This questionnaire is widely
used and recommended for measuring QoL in PD [20].
This study was approved by the Newcastle and North
Tyneside Research Ethics Committee. All participants
provided written informed consent.
Statistical analyses were performed using SPSS
Version 19.0. Comparisons of means between two
groups or more than two groups were performed using
independent t-tests, Mann-Whitney U test or Kruskal-
Wallis tests as appropriate..
RESULTS
There were no significant differences between PD
participants (n = 219) and controls (n = 99) in terms of
age (mean of 65.9 ± 9.7 vs 67.9 ± 8.2 years; p = 0.06),
sex (males 63.9% vs 55%; p = 0.11), level of education
(mean of 13.1 ± 3.4 vs 12.8 ± 3.6 years; p = 0.36) and
NART scores (mean of 115.8 ± 8.7 vs 114.3 ± 10.3;
p = 0.37). Mean duration of PD was 5.5 ± 5.0 months,
83% were rated as Hoehn and Yahr stage 1 or 2.
Using our modified MDS criteria 66% (n = 144)
were classified as having PD-MCI (≥1 SD below nor-
mative data); they were significantly older (p < 0.01),
had completed fewer years of education (p < 0.01) and
more severe motor symptoms (p < 0.01). QoL scores
were significantly worse for participants with PD-MCI
(mean of 24.3 ± 19.4 vs 31.2 ± 23.3; p = 0.03).
Participants were grouped by MCI severity, partici-
pants scoring: ≥1 SD but <1.5 SD below normative
data (PD-MCI 1SD, n = 51); ≥1.5 SD but <2 SD
below normative data (PD-MCI 1.5 SD, n = 44); and
≥2 SD below normative data (PD-MCI 2 SD, n = 49).
Post hoc analysis showed PDQ-39 scores were signif-
icantly worse using the 2 SD PD-MCI cut off (mean
of 38.2 ± 25.2; p = 0.01) compared to 1 SD and 1.5 SD
cut off (mean of 26.6 ± 21.9 and 28.8 ± 21.2 respec-
tively), suggesting that more severe MCI was a major
contributor to poor quality of life in the MCI group.
Subtypes of mild cognitive impairment
The MDS PD-MCI criteria identified 22 subtypes
(Fig. 1). Significantly more subjects were classi-
fied as having multi-domain than single-domain MCI
(p < 0.01). Executive function (67%), memory (61%)
and attention (51%) were most frequently impaired.
The most common subtypes were memory+executive
function (22%), attention+executive function (13%)
and attention+memory+executive function (13%). Fig-
ure 1 also shows that the number of participants in each
subtype was relatively small; the first seven subtypes
accounted for the majority of participants, with those
after the divide making up less than 5% of participants
in each subgroup.
Figure 2 shows a radar plot of the seven most fre-
quent subtypes and PDQ-39 score by PD-MCI cut
off; values extending from the centre of plot indicate
worse QoL. In most subtypes, QoL decreased as cog-
nitive impairment increased. Single-domain attention
and multi-domain attention+memory+executive func-
tion tended to be associated with poorer QoL at the 2
SD cognitive cut off compared to other cut offs, but
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Fig. 1. Subtypes of mild cognitive impairment in participants with newly diagnosed Parkinson’s disease. Subtypes of mild cognitive impairment
(MCI): A = Attention; E = Executive function; L = Language; M = Memory; V = Visuospatial function.
overall there were no significant differences in QoL
between MCI subtypes (p > 0.10).
We conducted a secondary analysis using classifica-
tions outlined by Marras, et al. [21], which required two
tests impaired in at least one domain. This identified
fewer PD-MCI participants (≥1 SD below normative
data; n = 104) with significantly more single-domain
impairments (76%). The most common subtypes were
single-domain executive function (25%) and memory
(19%); memory+executive function remained the most
common multiple-domain subtype (5%). There were
no significant differences in QoL between subtypes
(p > 0.10).
DISCUSSION
In this large incidence cohort, we found that QoL
decreased as severity of MCI increased. We identified
a number of PD-MCI subtypes and found more multi-
domain impairments than single-domain, although
there were no significant differences in QoL between
subtypes. This may suggest that in PD-MCI it is the
severity of cognitive impairment, rather than the nature
of impairment, that impacts on QoL.
Impairment was most common in executive func-
tion, memory and attention. Two thirds of PD-MCI
participants had executive dysfunction. A recent study
has also observed high frequencies of executive dys-
function in PD-MCI [22], which can impair ADL
[8]. Memory was the second most common impaired
domain, which was also reported by Goldman, et al.
[22], and has been shown to negatively impact on
QoL [23, 24]. Half of PD-MCI participants had atten-
tional dysfunction, which was also the most common
single-domain subtype. This has also been observed
in a previous study [25] and has been shown to
significantly impact physical functioning and social
interaction [5]. Significantly, only 15% of PD-MCI
subjects had single-domain impairment. The high pro-
portion of multi-domain impairments has also been
found in other studies [21, 22, 26, 27].
To our knowledge, this is the first study to explore
the relationship between QoL and PD-MCI subtypes.
More severe impairment in single-domain atten-
tion and multi-domain attention+memory+executive
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Fig. 2. Subtypes of mild cognitive impairment and PDQ-39 scores. Radar plot of mean PDQ-39 scores of each cut-off, (1 SD, 1.5 SD and
2 SD below normative values) for the most frequent subtypes of mild cognitive impairment. Scale on graph is PDQ-39 score, where higher
values indicate worse quality of life. A = Attention; E = Executive function; L = Language; M = Memory; V = Visuospatial function; PDQ-
39 = Parkinson’s Disease Questionnaire.
function subtypes tended to be associated with poorer
QoL, although we did not find any significant differ-
ences in QoL score between subtypes. Previous studies
have variable findings between cognitive domains.
Attention and memory problems have been associ-
ated with worse QoL [23], whilst another study found
visuospatial function, executive function and atten-
tion in PD participants affected QoL [4]. Impairment
in specific domains can inhibit everyday function-
ing and ADL [5], or results in less effective coping
strategies [6]. Therefore, there may be an interaction
between PD-MCI and other lifestyle variables; those
with higher premorbid functioning may find the chal-
lenge of having MCI greater [24].
The strength of this study is in the large cohort of
newly diagnosed PD participants with an age-matched
control group. Limitations include its design that pre-
ceded the publication of the MDS PD-MCI criteria.
We therefore used a modified version with an unequal
numbers of tests per domain comprising only one test
for visuospatial function and more than two tests for
memory and executive function. This has implica-
tions for subtyping and may increase the frequency
of impairments in these domains. The small number of
participants in each subtype reduced statistical power,
decreasing the sensitivity of our study to detect subtle
differences between subtypes.
In summary, PD-MCI is complex with severity of
impairment, rather than subtype, affecting QoL. It
could be inferred that the current MDS guidelines for
subtyping PD-MCI may not be optimal, we identified
22 subtypes using the proposed guidelines. Numerous
subtypes may be impractical in clinical settings; this
could indicate that subtyping is of no real significance
to patients and that their QoL is not affected by the
specific nature of the impairment.
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